Company Profile

FzioMed Inc
Profile last edited on: 12/19/18      CAGE: 4CSF8      UEI:

Business Identifier: Biomaterials for surgical adhesion prevention
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

231 Bonetti Drive
San Luis Obispo, CA 93401
   (805) 546-0610
Location: Single
Congr. District: 24
County: San Luis Obispo

Public Profile

FzioMed is a privately held medical device company organized around FzioMed develops, manufactures, and commercializes absorbable, surgical biomaterials used by surgeons as adhesion barriers to improve surgical outcomes. Products developed by FzioMed include Oxiplex®, Oxiplex/SP® Gel, MediShield™, and Interpose®. The spine adhesion barrier gel is the number 1 adhesion prevention treatment worldwide. Surgeons also use FzioMed products for orthopedics, hand, tendon, peripheral nerve, peritoneal and intrauterine procedures. Other products include DYNAVISC®, Oxiplex/AP®, and Oxiplex/IU®. based on the firm's patented polymer science. The firm's product platform is an innovative polymer technology called Oxiplex(tm) and forms the basis of the firm's development of a variety of biocompatible, absorbable Oxiplex(tm) products for targeted surgical and medical application. FzioMed adhesion barriers are used in many surgical applications including spine, orthopedics, hand, tendon, peripheral nerve, and peritoneal/abdominal. The firm's spine gel is rated very high as the adhesion barrier gel of choice for spine surgery wor

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 1 NIH $100,000
Project Title: Injectable Delivery of Bone Growth Factor, HomoSer3-AIII
1997 1 NIH $100,000
Project Title: Bioadhesive Barrier For The Prevention Of Adhesions

Key People / Management

  Ronald F Haynes -- Founder and Executive Chair

  John S Loveman-Krelle -- Chief Executive Officer and President

  Richard A Berg -- Vice President of Research and Development

  Herbert E Schwartz

Company News

There are no news available.